23 January 2026 : Clinical Research
Predicting the Effectiveness of 2 Chemotherapy Regimens Applied to Breast Cancer Patients by Nutritional and Inflammatory Status
Mehmet Salim Demir
ABCDEFG 1*, Gözde Ağdaş BCFG 1
DOI: 10.12659/MSM.951548
Med Sci Monit 2026; 32:e951548
Table 2 Comparison of characteristics between neoadjuvant chemotherapy groups.
| Features | ddAC-THP (n: 72) | TCHP (n: 40) | P value |
|---|---|---|---|
| Her2 IHK +2/FISH (+) | 31 (43.1%) | 16 (40%) | 0.754 |
| Her2 IHK +3 | 41 (56.9%) | 24 (60%) | |
| Her2-FISH (+) | 31 (43.1%) | 16 (40%) | |
| Estrogen receptor (+) | 50 (69.4%) | 29 (72.5%) | 0.685 |
| Progesterone receptor (+) | 44 (61.1%) | 28 (70%) | 0.462 |
| Ki-67 positive | 71 (98.6%) | 40 (100%) | 0.454 |
| Differentiation | 0.874 | ||
| Grade 1 | 12 (16.9%) | 6 (15.0%) | |
| Grade 2 | 45 (63.4%) | 27 (67.5%) | |
| Grade 3 | 14 (19.4%) | 7 (17.5%) | |
| cT Stage | 0.417 | ||
| T1 | 2 (2.8%) | 3 (7.5%) | |
| T2 | 22 (30.6%) | 15 (37.5%) | |
| T3 | 43 (59.7%) | 21 (52.5%) | |
| T4 | 5 (6.9%) | 1 (2.5%) | |
| Clinical nodule positive | 64 (88.9%) | 32 (80%) | 0.198 |
| Ductal histology present | 62 (86.1%) | 36 (90%) | 0.551 |
| Lobular histology present | 10 (13.9%) | 4 (10%) | |
| TCHP – docetaxel, carboplatin, trastuzumab, and pertuzumab; ddAC-THP – dose-dense doxorubicin-cyclophosphamide followed by docetaxel, trastuzumab, and pertuzumab; IHC – immuno-histochemistry; FISH – fluorescence in situ hybridization. Categorical variables are expressed as counts with percentages (n,%) and compared using the chi-square or Fisher’s exact test where appropriate. A two-tailed value | |||